Physician profile
Robert A Egan
NPI 1396771358
$31,837.97
in general payments reported to CMS, 2019-2025
33 companies · $80.47 in 2025
The $80.47 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $2,683 · 2021: $333 · 2022: $1,028 · 2023: $5,893 · 2024: $158 · 2025: $80.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,960 · Food and Beverage: $1,217 · Travel and Lodging: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,960.00 |
| Food and Beverage | $1,217.06 |
| Travel and Lodging | $953.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23,431.44 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $5,285.37 | 2023 | |
| Abbvie INC. | $436.33 | 2021-2023 | Ubrelvy, Qulipta |
| Genzyme Corporation | $398.10 | 2019-2023 | |
| Lilly USA, LLC | $241.72 | 2019-2024 | Emgality |
| Sk Life Science, INC. | $202.89 | 2022-2023 | Xcopri |
| Alexion Pharmaceuticals, INC. | $179.34 | 2022 | |
| Boston Scientific Corporation | $147.25 | 2022 | |
| Amgen INC. | $141.45 | 2019-2024 | Uplizna |
| Emd Serono, INC. | $129.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $124.58 | 2019 | |
| Biogen, INC. | $102.41 | 2022-2023 | Vumerity, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $102.14 | 2022 | |
| Spark Therapeutics, INC. | $100.89 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $99.97 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $94.92 | 2022 | |
| Corium, LLC | $92.13 | 2023 | Adlarity |
| Merz Pharmaceuticals, LLC | $70.75 | 2023 | Xeomin |
| Catalyst Pharmaceuticals, INC. | $62.47 | 2025 | |
| Greenwich Biosciences, INC. | $61.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.28 | 2019 | |
| Neurocrine Biosciences, INC. | $36.59 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $30.97 | 2019 | |
| Lundbeck LLC | $30.40 | 2023 | Vyepti |
| Tanabe Pharma America, INC. | $29.39 | 2019 | |
| Acadia Pharmaceuticals INC | $28.35 | 2019 | |
| Csl Behring | $23.32 | 2019 | |
| Irhythm Technologies, INC. | $19.47 | 2022 | |
| Novo Nordisk INC | $18.00 | 2025 | Wegovy |
| Genentech USA, INC. | $17.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.44 | 2019 | |
| Medtronic Vascular, INC. | $14.38 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.